PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for...
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial...
PolyPid collaborates with ImmunoGenesis to enhance solid tumor treatment using innovative drug delivery technologies.Quiver AI SummaryPolyPid Ltd. has announced a collaboration with ImmunoGenesis, Inc....
PolyPid Ltd. faces Nasdaq non-compliance but has potential funding options to regain stockholder equity requirements.Quiver AI SummaryPolyPid Ltd., a late-stage biopharma company focused on improving surgical...
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus...